Skip to content

Pioneering For Patients™

"After 25,000 patients treated, I know what works. Now Shackelford Pharma is bringing these treatments to the world."

- Dr. Alan Shackelford

the endocannabinoid system

The endocannabinoid system, only discovered in recent decades, may play a critical role in many important bodily functions and their dysfunction. The system has been implicated in key neurological conditions such as seizures and cognitive impairment.

Real-world evidence

Shackelford Pharma is built on Dr. Shackelford's real world evidence and insights. Over 25,000 real patients with real outcomes. SPI's team studied this patient database to identify the best therapeutic candidates for commercial development. Shackelford Pharma has exclusive access to this data.

Pioneering Orphan Drugs

"Orphan" diseases are rare conditions that affect small groups of people. Thanks to Dr. Shackelford's patient data base, we have multiple orphan drug candidates for potential drug development such as rare childhood epileptic syndromes.

"After CNN featured Alan's groundbreaking treatment of Charlotte for her seizures, parents brought in kids from all over the USA and world. The parents would give up everything for the treatment and products their kids needed!"


therapeutic focus

Shackelford Pharma has created one of the most promising pipelines in the industry. The company is developing therapeutics for neurological conditions with an initial focus on cognitive impairment and rare epileptic disorders.

testimonial from one of dr. shackelford's patients

"A team of doctors had me on 13 different pills. The side effects were horrendous. After seeing Dr. Shackelford, I went home and used his formulation for the first time. My husband and my parents cried, because they saw life in my eyes again."


Invest in Shackelford

Shackelford Pharma’s Regulation A Financing is now open. Investors are required to fill out the form below to begin the investment process.

Please check your JUNK/SPAM email folder if your invitation email from Dealmaker/Shackelford does not arrive in your inbox.

Invest Shackelford